Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025

Published on 2025-04-28 at 04:30

S&P Capital IQ

-0.09%

Shenyang Xingqi Pharmaceutical Co.,Ltd. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported sales was CNY 536.14 million compared to CNY 349.88 million a year ago. Revenue was CNY 536.14 million compared to CNY 349.88 million a year ago.

Net income was CNY 145.9 million compared to CNY 34.75 million a year ago. Basic earnings per share from continuing operations was CNY 0.5929 compared to CNY 0.1429 a year ago. Diluted earnings per share from continuing operations was CNY 0.5929 compared to CNY 0.1429 a year ago.

Latest news about Shenyang Xingqi Pharmaceutical Co.,Ltd.

Xingqi Pharmaceutical Begins Phase Three Trial for Anesthetic Gel	06-17	MT
Xingqi Pharmaceutical Says No Adverse Effects Seen in Phase 1 Eye Drops Trial	05-30	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 850 million in funding	05-26	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	04-28	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	04-20	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	24-10-28	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(XSEC:300573) added to FTSE All-World Index	24-09-22	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	24-08-28	CI
Xingqi Pharmaceutical Gets Nod to Trial Eye Drops; Shares Up 4%	24-07-25	MT
Xingqi Pharmaceutical Gets Nod to Register Bromfenac Sodium Eye Drops; Shares Down 3%	24-07-24	MT
Space Peptides announced that it has received funding from Humanwell Healthcare Co.,Ltd., Shenyang Xingqi Pharmaceutical Co.,Ltd., Xiamen Furuier Pharmaceutical Co., Ltd., Purple Knight Capital and other investors	24-05-21	CI
Shenyang Xingqi Pharmaceutical's Q1 Profit Jumps 80%	24-04-26	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	24-04-25	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	24-04-18	CI
Xingqi Pharma Gets Nod to Market Atropine Sulfate Eye Drop; Shares Up 3%	24-03-13	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Board Elections	24-01-08	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(SZSE:300573) added to Shenzhen Stock Exchange Component Index	23-12-12	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(SZSE:300573) added to Shenzhen Stock Exchange Component A Share Index	23-12-12	CI
Xingqi Pharmaceutical's Diquafosol Sodium Eye Drops Bags China's Centralized Drug Bid	23-11-08	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-23	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Xingqi Pharmaceutical Enrolls First Subject for Phase 4 Trial of Eye Drops	23-08-17	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-19	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI